• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

AbCellera Biologics (ABCL)

Ordinary Shares
Sell: $3.28|Buy: $3.40|Change: 0.09 (-2.51%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635.

Address

1300 - 777 Dunsmuir Street
Pacific Centre
Vancouver
BC
CAN
V7Y 1K2

Telephone

+1 604 559-9005

Website

https://www.abcellera.com

Sector 

Healthcare

Forecast key dates

NameKey Date
AbCellera Biologics Inc Fourth Quarter Earnings Conference Call for 20262027-02-24T17:00:00
AbCellera Biologics Inc Fourth Quarter Earnings Results for 20262027-02-24T00:00:00
AbCellera Biologics Inc Annual Report for 20262027-02-24T00:00:00
AbCellera Biologics Inc Third Quarter Earnings Conference Call for 20262026-11-06T17:00:00
AbCellera Biologics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
AbCellera Biologics Inc Second Quarter Earnings Conference Call for 20262026-08-07T17:00:00
AbCellera Biologics Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
AbCellera Biologics Inc Annual General Meeting for 20262026-06-12T09:00:00
AbCellera Biologics Inc First Quarter Earnings Conference Call for 20262026-05-11T17:00:00
AbCellera Biologics Inc First Quarter Earnings Result for 20262026-05-11T00:00:00

Previous key dates

NameKey Date
KeyBanc Capital Markets Healthcare Forum2026-03-17T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-04T09:50:00
AbCellera Biologics Inc Fourth Quarter Earnings Conference Call for 20252026-02-24T17:00:00
AbCellera Biologics Inc Fourth Quarter Earnings Results for 20252026-02-24T00:00:00
AbCellera Biologics Inc Annual Report for 20252026-02-24T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-14T15:45:00
Piper Sandler 37th Annual Healthcare Conference2025-12-03T08:00:00
Jefferies Global Healthcare Conference2025-11-20T13:00:00
AbCellera Biologics Inc Third Quarter Earnings Conference Call for 20252025-11-06T17:00:00
AbCellera Biologics Inc Third Quarter Earnings Result for 20252025-11-06T00:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T09:00:00
Wells Fargo Healthcare Conference2025-09-05T09:30:00
AbCellera Biologics Inc Second Quarter Earnings Conference Call for 20252025-08-07T17:00:00
AbCellera Biologics Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
AbCellera Biologics Inc Annual General Meeting for 20252025-06-12T09:00:00
AbCellera Biologics Inc First Quarter Earnings Conference Call for 20252025-05-08T17:00:00
AbCellera Biologics Inc First Quarter Earnings Result for 20252025-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.